MS
LRMR icon

Maven Securities’s Larimar Therapeutics LRMR Stock Holding History

Maven Securities’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,775
Closed -$26K – 1200
2021
Q1 		$26K Buy
+1,775
New +$32.3K ﹤0.01% 1138
2018
Q3 		– Sell
-10,417
Closed -$1.25M – 164
2018
Q2 		$1.25M Buy
+10,417
New +$885K 0.69% 34

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Maven Securities's LRMR Position: Q2 2021 in Review

Maven Securities sold out of Larimar Therapeutics (LRMR) in Q2 2021, closing a stake of 1,775 shares — an estimated $26K sold.

Maven Securities first reported a position in LRMR in Q2 2018 and held it in 2 quarters. The position peaked at $1.25M in Q2 2018. 45 funds tracked by Wall St. Rank hold LRMR as of Q2 2021.

  • Maven Securities reported no remaining Larimar Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 1,775 Larimar Therapeutics shares in Q2 2021, an estimated $26K.
  • Maven Securities first reported a position in Larimar Therapeutics in Q2 2018 and held it in 2 quarters.
  • Maven Securities's Larimar Therapeutics position peaked at $1.25M in Q2 2018.
  • 45 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.